Central IRB Approved for ABV-1505 Phase II Part II in Taiwan Sites
ABVC BioPharma Receives Taiwan Regulatory Approval for ABV-1505 ADHD Phase II Part 2 Clinical Study Completion of the Study Expected by the End of 2022 FREMONT, CA, Oct. 27, 2021…